Postgraduate Course in Cardiometabolic Medicine 2026
-
Ort
London, UK
Type of event
on site
Special weekend offer! Early Bird extended until 10 May 2026—secure your spot now.
This event was developed by London Heart House.
AstraZeneca, Novo Nordisk and Novartis have provided sponsorship in the form of financial support towards this event. The sponsoring companies have had no influence over the agenda, content development or choice of speakers, except for the sponsored symposia presentations, which are organised by the respective named sponsor per session. The sponsoring companies have been granted exhibition space at this conference.
AstraZeneca has provided sponsorship towards this independent Programme and has had no involvement in its creation or organisation.
Invitation
Dear Colleagues
It is a pleasure to announce the 3rd Postgraduate Course in Cardiometabolic Medicine, a timely and highly acclaimed educational programme conceived by Zurich Heart House – London Heart House, King’s College, and Royal Brompton & Harefield Hospitals, which will address an unmet educational need.
Cardiometabolic disorders represent a cluster of interrelated risk factors, primarily dyslipidemia, hypertension, elevated fasting blood glucose, obesity and non-alcoholic steatohepatitis. A combination of several of these risk factors massively increases the incidence and mortality of coronary heart disease and stroke. The strong association between metabolic disorders and cardiovascular health delivers a compelling reason to improve awareness of this cluster by identifying the risk factors and inducing targeted interventions.
The Postgraduate Course in Cardiometabolic Medicine consists of a three-day programme. State of the art lectures alternate with a great variety of interactive sessions, including workshops, rapid fire sessions and hands-on imaging sessions.
The course offers a unique opportunity to become an expert in the seminal area of cardiometabolic medicine. We would be most happy to welcome you at the Royal Society of Medicine in central London to enjoy three days of interactive education for the benefit of your practice and your patients.
Sincerely,
Andrew Krentz
Thomas F. Lüscher
John E. Deanfield
Michael Papadakis
Programme
Day 1, Thursday, June 4th, 2026
Venue: Hallam Conference Centre, London
| 09:00 - 09:30 | REGISTRATION AND COFFEE | |
|---|---|
| 09:30 - 09:45 | Opening Session | |
| 09:30 | Welcome by the course directors & Course concept and structure |
| 09:45 - 11:30 | Session 1: Obesity, Comorbidities and their management Chairs: Andrew Krentz & Michael Papadakis | ||
|---|---|---|
| 09:45 | Is obesity a disease? If so, how do we diagnose it? The Lancet Diabetes and Endocrinology Commission | Francesco Rubino, London |
| 10:05 | Obesity and inflammation | Fiona McGillicuddy, Dublin |
| 10:25 | Obesity, comorbidities and CV prevention | Geltrude Mingrone, London/Rome |
| 10:45 | What links adiposity to CVD? | Konstantinos Koskinas, Bern |
| 11:05 | Panel discussion | |
| 11:30 - 12:00 | COFFEE | ||
| 12:00 - 12:30 | Keynote Lecture | ||
|---|---|---|
| 12:00 | How to address obesity globally? | John E. Deanfield, London |
| 12:30 - 13:30 | Session 2: Lifestyle and cardiovascular prevention Chairs: Thomas F. Lüscher & John E. Deanfield | ||
|---|---|---|
| 12:30 | Nutrition: from diet to the microbiome | Vassilios Vassiliou, Norwich |
| 12:45 | Exercise and sports for cardiovascular disease prevention | Michael Papadakis, London |
| 13:00 | Is vaping the new smoking frontier? | Thomas Münzel, Mainz |
| 13:15 | Panel discussion | |
| 13:30 – 14:15 | Industry Sponsored Symposium tbd | ||
| 14:15 - 15:00 | LUNCH BREAK | ||
| 15:00 - 16:30 | Session 3: ASCVD Assessment I Chairs: Mahmoud Barbir & Eleanor Wicks | ||
|---|---|---|
| 15:00 | 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias | François Mach, Geneva |
| 15:20 | LDL-C and cardiovascular disease: Why is lower better? | Lale Tokgözoğlu, Ankara |
| 15:40 | Hypertension: Lifestyle, medication or intervention? The 2024 ESC and ESH Guidelines on Hypertension | Sofie Brouwers, Aalst |
| 16:00 | Panel discussion | |
| 16:30 - 16:45 | COFFEE | ||
| 16:45 - 17:45 | Case-based interactive seminars I | ||
| Managing cardiovascular aspects in an athlete – case presentation | Michael Papadakis, London | |
| Cardiovascular Check-up in the general population – the EU strategy | François Mach, Geneva | |
DAY 2, Friday, June 5th, 2026
| 09:00 - 10:45 | Session 4: ASCVD Assessment II & Management Chairs: Lale Tokgözoğlu & Christian Heiss | ||
|---|---|---|
| 09:00 | Multimodality imaging to assess ASCVD | Chiara Bucciarelli-Ducci, London |
| 09:20 | Perivascular fat: Therapeutic target or surrogate of vascular disease? | Charalambos Antoniades, Oxford |
| 09:40 | Nucleic acids for LDL-C and Lipoprotein(a): anti-lipid effects and beyond | Ulf Landmesser, Berlin |
| 10:00 | Remnant cholesterol and triglycerides: really a cardiovascular risk factor? | Børge Nordestgaard, Copenhagen |
| 10:20 | Panel discussion | |
| 10:45 - 11:15 | COFFEE | ||
| 11:15 - 12:15 | Live demonstrations | ||
|---|---|---|
| Live in-a-box: Ergospirometry – how to do properly and interpret | Luke Howard, London | |
| Assessing vascular structure and function: a tool for primary prevention | Christian Heiss, Guildford | |
| 12:15 - 13:00 | Industry Sponsored Symposium tbd | ||
| 13:00 – 13:45 | LUNCH BREAK | ||
| 13:45 - 15:10 | Session 5: Diabetes mellitus (DM) Chairs: Thomas F. Lüscher & William Alazawi | ||
|---|---|---|
| 13:45 | Diabetes Type 2: Pathogenesis and management | Andrew Krentz, London |
| 14:05 | Management of CVD risk in type 2 diabetes – the 2023 ESC Diabetes guidelines | Dirk Müller-Wieland, Aachen |
| 14:25 | Inkretin-based therapy – diabetes and beyond | Malte Kelm, Düsseldorf |
| 14:45 | Panel discussion | |
| 15:10 - 16:10 | Session 6: Metabolic dysfunction-associated steatotic liver disease (MASLD) Chairs: Andrew Krentz & Eleanor Wicks | ||
|---|---|---|
| 15:10 | Screening and diagnosis of MASLD | Philip Newsome, London |
| 15:30 | Management of MASLD | William Alazawi, London |
| 15:50 | Panel discussion | |
| 16:10 - 16:30 | COFFEE | ||
| 16:30 - 17:10 | Session 7: Endocrinology and Cardiovascular disease Chairs: NN & Nikant Sabharwal | ||
|---|---|---|
| 16:30 | Cardiovascular risk in classic endocrine disease | Adrian Heald, Manchester |
| 16:50 | Sex hormones and CVD: in athletes and the population at large | Andrew Krentz, London |
| 17:10 | Panel discussion | |
| 17:30 – 18:30 | Case-based interactive seminars II | ||
| Managing type 2 diabetes and CVD risk – patient cases | Matthew Waite, London | |
| Diagnosing MASLD with Fibroscan – patient cases | William Alazawi, London | |
DAY 3, Saturday, June 6th, 2026
| 09:00 - 10:00 | Session 8: Nephrology - Chronic Kidney Disease (CKD) – Causes & Mechanisms Chairs: Kieran McCafferty & Tomasz Guzik | ||
|---|---|---|
| 09:00 | CKD and cardiovascular risk | Parminder Judge, Oxford |
| 09:20 | Albuminuria, eGFR slopes and outcomes: impact of pharmacotherapy | Philip A. Kalra, Salford |
| 09:40 | Panel discussion | |
| 10:00 - 11:00 | Session 9: Nephrology - Chronic kidney disease (CKD) - Management Chairs: Thomas Lüscher & Parminder Judge | ||
|---|---|---|
| 10:00 | SGLT2i and GLP1-RA in CKD and DKD – the 4 pillar approach | Kieran McCafferty, London |
| 10:20 | Aldosterone synthase inhibition vs. receptor antagonism: what is better? | Tomasz Guzik, Edinburgh |
| 10:40 | Panel discussion | |
| 11:00 - 11:30 | COFFEE | ||
| 11:30 - 12:30 | Session 10: Cardiovascular risk in myocardial disease Chairs: Sohaib Nazir & Eleanor Wicks | ||
|---|---|---|
| 11:30 | Managing amyloid heart disease: from stabilizers to siRNA and CRISPR-Cas9 | Ana Martinez Naharro, London |
| 11:50 | Hypertrophic cardiomyopathy: diagnosis and management | Maurizio Pieroni, Florence |
| 12:10 | Panel discussion | |
| 12:30 - 13:30 | LUNCH | ||
| 13:30 - 15:00 | Session 11: Heart failure Chairs: Maurizio Pieroni & Shanti Velmurugan | ||
|---|---|---|
| 13:30 | Prevention and rehabilitation of heart failure | Ana Abreu, Lisbon |
| 13:50 | Management of heart failure: the 2021 and 2023 ESC guidelines | Theresa McDonagh, London |
| 14:10 | Prevention and rehabilitation in cancer patients | Sohaib Nazir, London |
| 14:30 | Panel discussion | |
| 15:00 - 15:30 | COFFEE | ||
| 15:30 – 16:30 | Case-based interactive seminars III | ||
| Managing patients with CKD – patient cases | Philip A. Kalra, Salford | |
| Assessing HFpEF and HFrEF with echocardiography – patient cases | Rajdeep Khattar, London | |
The programme may be subject to change.
Information
Registration
| Category | |
|---|---|
| Registration fees | |
| Early registration fee (until May 3rd, 2026) | GBP 400 |
| Regular course fee | GBP 450 |
| Early registration fee (until May 3rd, 2026): Trainees/Residents, Research fellows, Nurses, Students <40 years (ID proof required)* | GBP 200 |
| Trainees/Residents, Research fellows, Nurses, Students <40 years (ID proof required)* | GPB 250 |
| Day Tickets | GPB 150 |
*For the reduced registration (Trainees/Residents, Research fellows, Nurses, Students <40 years) please send a copy of your ID to Ms. Christine Lohmann at christine.lohmann@zhh.ch
Registration will be confirmed upon receipt of payment.
Please note that UK banks may charge high fees for international bank transfers. We therefore recommend payment by credit card.
Travel Information
Travel to London
You must have a valid passport to enter the UK. It should be valid for the whole of your stay. You may also need a visa, depending on which country you’re from and the reason for your stay. Check if you need a visa to come to the UK. You must have your visa before you travel to the UK.
Electronic travel authorisation (ETA)
From 2 April 2025, EU citizens will require an Electronic Travel Authorisation (ETA) to enter the UK. For non-EU citizens, the regulation will come into force on 8 January 2025. More information can be found on https://www.gov.uk/guidance/apply-for-an-electronic-travel-authorisation-eta. It will be possible to apply for the ETA, which will be required from April, from 5 March 2025 onwards. For nationals of certain countries outside Europe, the ETA will be required from 8 January 2025. The application is again possible from 27 November 2024: https://www.gov.uk/guidance/check-when-you-can-get-an-electronic-travel-authorisation-eta. You won’t have to apply in case you have a VISA.
Modification & Cancellation
All modifications or cancellations must be notified in writing (by mail, fax or e-mail) to Zurich Heart House. For each modification requested by the participant, GBP 15 will be charged for administrative costs. In case of cancellation up to May 8th, 2026, deposits will be refunded less 35% for administrative costs. After this date, no refund will be possible.
Venue
Hallam Conference Centre, London,
Cavendish Venues - 44 Hallam Street, W1, United Kingdom
Organisation
Zurich Heart House, / London Heart House, Foundation for Cardiovascular Research
Eleanor Wicks
Christine Lohmann
Hottingerstrasse 14, CH-8032 Zurich, Switzerland
Phone +41 (0) 44 250 40 95
www.zhh.ch / www.londonhearthouse.uk
Accreditation
The Postgraduate Course in Cardiometabolic Medicine 2026 has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 18 category 1 (external) CPD credit(s).
The Postgraduate Course in Cardiometabolic Medicine 2026 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 17.5 European CME credits (ECMEC®s).
Organized by
Endorsed by
Scan to Register here
Anmeldeschluss